SCHEMBL31395339

SCHEMBL31395339

CC(=O)Nc1cnc(Oc2ccc(F)cc2)c(-c2cn(C)c(=O)c3c2ccn3S(=O)(=O)c2ccc(C)cc2)c1

nearest known ligand 0.54

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ BRD4 O60885 19/20 0.54
▸ PIK3C3 Q8NEB9 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31395501 0.93 BRD4 (0.54) BRD4PIK3C3
SCHEMBL31395483 0.89 BRD4 (0.54) BRD4
SCHEMBL31395752 0.88 BRD4 (0.68) BRD4
SCHEMBL31395392 0.83 BRD4 (0.53) BRD4
SCHEMBL31395367 0.83 BRD4 (0.47) BRD4
SCHEMBL31395353 0.82 BRD4 (0.55) BRD4PIK3C3
SCHEMBL31395735 0.81 BRD4 (0.68) BRD4
SCHEMBL15069320 0.80 BRD4 (0.79) BRD4
SCHEMBL31395468 0.80 BRD4 (0.52) BRD4
SCHEMBL31395489 0.80 BRD4 (0.59) BRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4739307-A2 TARGETED EPIGENETIC THERAPIES FOR DISORDERS OF PROGRANULIN DEFICIENCY The General Hospital Corporation (US) 2026-05-13 — — EP disclosed
WO-2025010291-A2 TARGETED EPIGENETIC THERAPIES FOR DISORDERS OF PROGRANULIN DEFICIENCY THE GENERAL HOSPITAL CORPORATION (US) 2025-01-09 — — WO disclosed
Send feedback